PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Weill Medical College of Cornell University
Send
Updated on 16 February 2024
See if I qualify
cancer
adenocarcinoma
MRI
stereotactic body radiation therapy
non-metastatic prostate cancer
adenocarcinoma of prostate
metastatic prostate cancer
prostate cancer

Summary

Patients with metastatic prostate cancer can undergo MRI-guided prostate Stereotactic body radiation therapy (SBRT) without significant adverse events, similar to what has been reported for patients with localized prostate cancer. We hypothesize that prostate SBRT will be well-tolerated in metastatic prostate cancer patients, with quality of life outcomes similar to what has been reported in non-metastatic prostate cancer patients.

Description

The MRidian ViewRay offers delivery of prostate SBRT with real-time MR guidance, which provides superior soft-tissue differentiation with excellent visualization of the prostate. This ViewRay platform offers the ideal setting for this study, that aims at precisely delivering prostate SBRT with a simultaneous integrated boost (when indicated) to visible nodules.

In this study, we hope to demonstrate the safety and feasibility of using 36.25 Gy in 5 fractions, plus a simultaneous integrated boost (when indicated), in patients with metastatic prostate cancer.

Details
Condition Metastatic Prostate Cancer
Age 18years - 90years
Treatment MR-Guided Prostate SBRT
Clinical Study IdentifierNCT04220983
SponsorWeill Medical College of Cornell University
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Biopsy-proven diagnosis of prostate adenocarcinoma
Age 18
Must have biopsy-proven metastatic prostate cancer

Exclusion Criteria

History of prior pelvic radiation (external beam or brachytherapy)
Inability to undergo MRI
AUA score >20
Evidence of disease progression on bone scan, MR and/or CT
For patients on systemic therapy, enrollment must be within six months of start of therapy unless exception is made by protocol PIs
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
adenocarcinoma
MRI
stereotactic body radiation therapy
non-metastatic prostate cancer
adenocarcinoma of prostate
metastatic prostate cancer
prostate cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.